Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Pharmaceutical company records loss of $0.12 per share, reports on ALS drug
June 6th, 2005
Aeolus Pharmaceuticals, Inc., (AOLS.OB) announced the financial results for its second quarter of fiscal 2005, the 3-month period ended March 31, 2005, and provided an update on its drug for amyotrophic lateral sclerosis (ALS). Aeolus reported a net loss of $1,659,000, or $0.12 per share, for the 3 months ended March 31, 2005, and a net loss of $3,616,000, or $0.26 per share, for the 6 months ended March 31, 2005. This compares with a net loss of $2,308,000 for the 3 months ended March 31, 2004, and a net loss attributable to common stockholders of $4,786,000 for the 6 months ended March 31, 2004. On March 29, 2005, Aeolus announced interim results...
Source: Biotech Business Week (2005-06-06)
|
